Life-Threatening Myositis in a Patient With EGFR-Mutated NSCLC on Osimertinib: Case Report

Osimertinib is the standard of care for the first-line treatment of EGFR-mutated NSCLC. We report a case of a 52-year-old woman who developed life-threatening myopathy because of treatment with osimertinib. Limited instances of myositis have been previously reported in the literature; however, none...

Full description

Saved in:
Bibliographic Details
Published in:JTO clinical and research reports 2022-01, Vol.3 (1), p.100260, Article 100260
Main Authors: Crowley, Fionnuala, Fitzgerald, Bailey G., Bhardwaj, Aarti S., Siraj, Irine, Smith, Cardinale
Format: Article
Language:English
Subjects:
Case Report
EGFR
Myositis
NSCLC
Osimertinib
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Osimertinib is the standard of care for the first-line treatment of EGFR-mutated NSCLC. We report a case of a 52-year-old woman who developed life-threatening myopathy because of treatment with osimertinib. Limited instances of myositis have been previously reported in the literature; however, none have resulted in life-threatening oropharyngeal and respiratory muscle weakness as seen in this case. Care should be taken in administering osimertinib concurrently with other medications metabolized by the CYP3A4 system, and ongoing work to identify patients at risk for severe reactions is necessary. The use of routine creatinine phosphokinase monitoring should be considered as part of oncologic management.
ISSN:2666-3643
2666-3643
DOI:10.1016/j.jtocrr.2021.100260